12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ezatiostat hydrochloride tablets: Phase II data

A Phase II trial in 4 patients with severe ICN who were not responsive to G-CSF showed that oral ezatiostat increased white blood cell levels and led to "clinically significant"...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >